Compumedics secures approval for neuroimaging system for epilepsy and pre-surgical brain function mapping.
Medical device company Compumedics has received U.S. Food and Drug Administration approval for its brain activity-mapping neuroimaging technology, Orion LifeSpan™ Magnetoencephalography (MEG).
The 510(k) clearance greenlights the MEG single Dewar system that maps brain activity by recording magnetic fields that are generated by the brain’s natural electrical currents. Powered by the CURRY™ neuroimaging platform, Orion LifeSpan offers a dual-helmet system, enabling recordings for both adult and pediatric patients.
In addition, according to company information, the system is vibration-free and vacuum-cooled with zero-loss helium recycling. It also offers real-time video archiving and full cloud integration.
Based on a press statement, this technology, which sells for between $3-4 million, can primarily be applied in the clinical setting for epilepsy and pre-surgical brain function mapping. The Barrow Neurological Institute in Arizona has completed the first installation and first-phase commissioning of the system.
MRI Long Covid Study Reveals Link Between Lower Pulmonary Gas Exchange and Cognitive Dysfunction
November 26th 2024For patients with Long Covid, lower pulmonary gas exchange may be associated with lower gray and white matter volume, according to new MRI research to be presented at the Radiological Society of North America (RSNA) conference.
New DEXA Scan Study Links Thyroid Medication Levothyroxine to Higher Bone Loss Risk in Seniors
November 25th 2024Use of the medication levothyroxine, commonly prescribed for hypothyroidism, was associated with greater long-term loss of total body bone mass in seniors, according to new DEXA research to be presented at the Radiological Society of North America (RSNA) conference.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.